<!DOCTYPE html>
<style>
    .div {
        display: none;
    }

    .show {
        display: block;
    }
</style>

<script>
    var buttons = document.getElementsByTagName('button'),
        questions = document.getElementsByTagName('div');
    for (var i = 0; i < buttons.length; i++) {
        var button = buttons[i];
        console.log("check=====")
        button.addEventListener('click', function () {
            var target = this.getAttribute('data-next');
            for (var j = 0; j < questions.length; j++) {
                var question = questions[j];
                if (question.id == target) {
                    question.classList.add('show');
                } else if (question.classList.contains('show')) {
                    question.classList.remove('show');
                }
            }
        });
    }
</script>

<div id="Question1" class="show">
    (APPROVAL STEP 1) BUSINESS CASE PREPARATION & COUNTRY PRICING STRATEGY
</br></br>Primary Research for Pricing strategy<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button></br>
Is Price Points, HCP trialist, Affordable patients, patient share, No of patients completed<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button>
    </br></br>
    a.COUNTRY LEVEL</br>
    </br>
    i.total Revenues 2026 (value=7.6 million), 2027 (value=8 million)</br>
    ii.Total Direct M&S Cost before reversals 2026 (value=4 million) 2027 (value=3 million)</br>
    iii.Direct M&S Cost(MR-relevant) 2026 (value=4 million) 2027 (value=3 million)</br>
    iv.Marketing Contribution before COGS 2026 (value=4 million) , 2027 (value=3 million)</br>
    v.Strategic Product Charge(COGS) @30% 2026 (value=4 million) , 2027 (value=3 million)</br>
    vi.Marketing Contribution after COGS 2026 (value=4 million) , 2027 (value=3 million)</br>
      <button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button>
    </br></br>
    
    b.REGION LEVEL</br>
    </br>
    i.total Revenues 2026 (value=7.6 million), 2027 (value=8 million)</br>
    ii.Total Direct M&S Cost before reversals 2026 (value=4 million) 2027 (value=3 million)</br>
    iii.Direct M&S Cost(MR-relevant) 2026 (value=4 million) 2027 (value=3 million)</br>
    iv.Marketing Contribution before COGS 2026 (value=4 million) , 2027 (value=3 million)</br>
    v.Strategic Product Charge(COGS) @30% 2026 (value=4 million) , 2027 (value=3 million)</br>
    vi.Marketing Contribution after COGS 2026 (value=4 million) , 2027 (value=3 million)</br>
   <button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button>
    </br></br>
    c.GLOBAL LEVEL</br></br>
    i.total Revenues 2026 (value=7.6 million), 2027 (value=8 million)</br>
    ii.Total Direct M&S Cost before reversals 2026 (value=4 million) 2027 (value=3 million)</br>
    iii.Direct M&S Cost(MR-relevant) 2026 (value=4 million) 2027 (value=3 million)</br>
    iv.Marketing Contribution before COGS 2026 (value=4 million) , 2027 (value=3 million)</br>
    v.Strategic Product Charge(COGS) @30% 2026 (value=4 million) , 2027 (value=3 million)</br>
    vi.Marketing Contribution after COGS 2026 (value=4 million) , 2027 (value=3 million)</br>
    <button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button>
    </br></br>
    </br>
     APPROVAL STEP 2: HA - COUNTRY HEALTH AUTHORITY APPROVAL

    </br></br>
   Phase III trial<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button> 
    <button type="button" data-next="Question2">Not Required</button>
    </br>
    APPROVAL from EU/USFDA <button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button></br>
    Medical Rationale - is Unmet need is specified, value proposition of the molecule is stated and APPROVED by Country Medical Officer<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button></br>
    Site registration - Manufacturing unit from Germany set up/ process are done<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button></br>
    Dosier creation - when the above steps are also COMPLETED - Medical rationale, Phase III trial, unmet need, approval by EU/USFDA<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button></br>
    SEC meeting with HA HCPs should approve molecule proposal with medical rationale<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button></br>
    Are India patients included in phase III trial USFDA & EU approval for molecule.Yes = required, No= Not required<button type="button" data-next="Question2">Yes</button>
    <button type="button" data-next="Question3">No</button></br>
    </br></br>
     APPROVAL STEP 3: PACKAGING
     </br></br>
     APPROVAL STEP 4: SUPPLY & CHAIN
     </br></br>
     APPROVAL STEP 5: PRELAUNCH  (Parallel Step)
     </br></br></br><button type="button" data-next="Question3">Submit data </button></br></br></br>
</div>
<!-- <div id="Question2">
    2.Preparation
    <button type="button" data-next="Question4">Yes</button>
    <button type="button" data-next="Question5">No</button>
</div>
<div id="Question3">
    3.Total patient pool assess potential and forecast
    <button type="button" data-next="Question6">Yes</button>
    <button type="button" data-next="Question6">No</button>
</div>
<div id="Question4">
    4.Pricing projection to prepare Business case
    <button type="button" data-next="Question10">Yes</button>
    <button type="button" data-next="Question10">No</button>
</div> -->